Skip to main content
Company
Overview
Management
Supervisory Board
Research & Development
Portfolio overview
ADC technology
ATAC Projects
Out-licensed product candidates
Funded projects
Publications
Scientific posters
Partnering
Press & Investors
Strategy and Facts
Strategy
Facts
Shareholder information
Share, Shareholder Structure, Basic Information
Financing History
Analysts
Capital Increase
Announcements
Press Releases and Ad-hoc Announcements
Financial Reports
Voting Rights
Directors' Dealings
Calendar and Presentations
Conferences & Presentations
Financial Calendar
Annual General Meeting
Corporate Governance
Corporate Bodies and Shareholdings
Statement on Corporate Governance
Declaration of Conformity
Articles of Association
Rules of Procedure of the Supervisory Board
Remuneration system of the Management Board and Supervisory Board
Remuneration Reports
Compliance
Code of Conduct
Whistleblower system
Newsletter subscription
Career
Overview
Job offers
Application process
Contact
Imprint
Privacy Policy
Disclaimer
Supplier & partners
Contact
English
Deutsch
Company
Overview
Management
Supervisory Board
Research & Development
Portfolio overview
ADC technology
ATAC Projects
Out-licensed product candidates
Funded projects
Publications
Scientific posters
Partnering
Press & Investors
Strategy and Facts
Strategy
Facts
Shareholder information
Share, Shareholder Structure, Basic Information
Financing History
Analysts
Capital Increase
Announcements
Press Releases and Ad-hoc Announcements
Financial Reports
Voting Rights
Directors' Dealings
Calendar and Presentations
Conferences & Presentations
Financial Calendar
Annual General Meeting
Corporate Governance
Corporate Bodies and Shareholdings
Statement on Corporate Governance
Declaration of Conformity
Articles of Association
Rules of Procedure of the Supervisory Board
Remuneration system of the Management Board and Supervisory Board
Remuneration Reports
Compliance
Code of Conduct
Whistleblower system
Newsletter subscription
Career
Overview
Job offers
Application process
PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
Download Press Release
